Meta Pulls Inward, Pharma Leans In, and AI Governance Gets Messier
Published on 17.04.2026
Meta pivots from open weights
TLDR: Meta appears to be moving away from its open-weights posture toward a more closed strategy around future flagship models. That is a strategic shift with bigger implications than one product launch.
Big pharma bets big on AI
TLDR: Pharmaceutical companies are increasing their AI investments, especially where models can accelerate research and drug development workflows. The story is less about hype now and more about where large incumbents think real leverage might exist.
U.S. states move forward with AI laws
TLDR: State-level AI regulation in the U.S. is advancing in a patchwork rather than through one clean national framework. That means compliance will likely become more fragmented before it becomes simpler.
Simulating diverse human cohorts
TLDR: Synthetic human cohorts are being used to model how different groups might respond to products, messages, or decisions. The idea is compelling, but it sits right on the border between useful approximation and elegant self-deception.